HEALTH CARE RESOURCE USE OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY IN SWEDEN

被引：0
|
作者：
Lauppe, R. [1 ]
Hansen, Liseth J. [1 ]
Fornwall, A. [1 ]
Gerdeskold, C. [2 ]
Rozenbaum, M. [3 ]
Strand, A. [4 ]
Vakevainen, M. [5 ]
Kuusisto, J. [6 ,7 ]
Gude, E. [8 ]
Gustafsson, F. [9 ]
Smith, J. G. [10 ]
机构：
[1] Quantify Res, Stockholm, Sweden
[2] Pfizer Innovat AB, Stockholm, Sweden
[3] Pfizer Inc, Capelle Aan Den Ijssel, Netherlands
[4] Pfizer ApS, Ballerup 84, Denmark
[5] Pfizer Oy, Helsinki, Finland
[6] Univ Eastern Finland, Kuopio, Finland
[7] Kuopio Univ Hosp, Kuopio, Finland
[8] Oslo Univ Hosp, Rikshosp, Oslo, Norway
[9] Rigshosp, Copenhagen, Denmark
[10] Lund Univ, Lund, Sweden
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSB112
引用
收藏
页码：S83 / S83
页数：1
相关论文
共 50 条
  • [1] Health care resource use, diagnostic delay and disease burden in transthyretin amyloid cardiomyopathy in Sweden
    Hjalte, Frida
    Norlin, Jenny M.
    Alverbaeck-Labberton, Linda
    Johansson, Katarina
    Wikstrom, Gerhard
    Eldhagen, Per
    ANNALS OF MEDICINE, 2023, 55 (02)
  • [2] HEALTH CARE RESOURCE USE AND COSTS IN TRANSTHYRETIN AMYLOID CARDIOMYOPATHY - A SWEDISH MEDICAL RECORD REVIEW STUDY
    Hjalte, F.
    Norlin, J.
    Alverback-Labberton, L.
    Johansson, K.
    Wikstrom, G.
    Eldhagen, P.
    VALUE IN HEALTH, 2022, 25 (12) : S141 - S141
  • [3] Healthcare resource use of patients with transthyretin amyloid cardiomyopathy
    Lauppe, Rosa
    Hansen, Johan Liseth
    Fornwall, Anna
    Johansson, Katarina
    Rozenbaum, Mark H.
    Strand, Anne Mette
    Vakevainen, Merja
    Kuusisto, Johanna
    Gude, Einar
    Smith, J. Gustav
    Gustafsson, Finn
    ESC HEART FAILURE, 2022, 9 (03): : 1636 - 1642
  • [4] THE EPIDEMIOLOGY OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY IN SWEDEN
    Lauppe, R.
    Hansen, Liseth J.
    Sandin, P.
    Gerdeskold, C.
    Rozenbaum, M. H.
    Strand, A.
    Vakevainen, M.
    Kuusisto, J.
    Gude, E.
    Gustafsson, F.
    Smith, J. G.
    VALUE IN HEALTH, 2020, 23 : S699 - S699
  • [5] Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden
    Lauppe, Rosa Elisabeth
    Hansen, Johan Liseth
    Gerdeskold, Christian
    Rozenbaum, Mark H.
    Strand, Anne Mette
    Vakevainen, Merja
    Kuusisto, Johanna
    Gude, Einar
    Gustafsson, Finn
    Smith, J. Gustav
    OPEN HEART, 2021, 8 (02):
  • [6] Standardising Care and Treatment of Transthyretin Amyloid Cardiomyopathy
    Fontana, Marianna
    Porcari, Aldostefano
    Hawkins, Philip N.
    GLOBAL HEART, 2023, 18 (01)
  • [7] Clinical characteristics and health care resource use of patients at risk for wild-type transthyretin amyloid cardiomyopathy identified by machine learning model
    Bruno, Marianna
    Sheer, Richard
    Reed, Casey
    Schepart, Alexander
    Nair, Radhika
    Simmons, Jeff D.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2023, 29 (05): : 530 - 540
  • [8] Transthyretin amyloid cardiomyopathy
    Famularo, Giuseppe
    Ventroni, Guido
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2023, 366 (02): : E25 - E25
  • [9] Transthyretin amyloid cardiomyopathy
    Garcia-Pavia, Pablo
    Dominguez, Fernando
    Gonzalez-Lopez, Esther
    MEDICINA CLINICA, 2021, 156 (03): : 126 - 134
  • [10] Transthyretin amyloid cardiomyopathy
    Czepluch, Frauke
    INNERE MEDIZIN, 2023, 64 (09): : 823 - 829
12345